Biogen Inc Drug Patent Portfolio

Biogen Inc owns 3 orange book drugs protected by 23 US patents Given below is the list of Biogen Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11884696 Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid 24 Dec, 2037
Active
US11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid 23 Aug, 2037
Active
US10959972 Methods of treating multiple sclerosis 16 Nov, 2035
Active
US11007166 Methods of treating multiple sclerosis 16 Nov, 2035
Active
US11007167 Methods of treating multiple sclerosis 16 Nov, 2035
Active
US11129806 Methods of treating multiple sclerosis 16 Nov, 2035
Active
US11246850 Methods of treating multiple sclerosis 16 Nov, 2035
Active
US10391160 Dimethyl fumarate and vaccination regimens 13 Mar, 2035
Active
US10555993 Dimethyl fumarate and vaccination regimens 13 Mar, 2035
Active
US10994003 Dimethyl fumarate and vaccination regimens 13 Mar, 2035
Active
US10172871 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof 17 Apr, 2034
Active
US10342810 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof 17 Apr, 2034
Active
US9512165 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof 17 Apr, 2034
Active
US10080733 Prodrugs of fumarates and their use in treating various diseases 20 Sep, 2033
Active
US8669281 Prodrugs of fumarates and their use in treating various diseases 20 Sep, 2033
Active
US9090558 Prodrugs of fumarates and their use in treating various diseases 20 Sep, 2033
Active
US8399514 Treatment for multiple sclerosis 07 Feb, 2028
Active
US7320999 Dimethyl fumarate for the treatment of multiple sclerosis 18 May, 2020 Expired
US6509376 Utilization of dialkyfumarates 29 Oct, 2019 Expired
US8759393 Utilization of dialkylfumarates 04 Jul, 2018 Expired
US7619001 Utilization of dialkylfumarates 01 Apr, 2018 Expired
US7803840 Utilization of dialkylfumarates 01 Apr, 2018 Expired
US8524773 Utilization of dialkylfumarates 01 Apr, 2018 Expired


Given below is the list of recent legal activities going on the following drug patents of Biogen Inc.

Activity Date Patent Number
Patent litigations
Resp. to req. for info. sent under 37 CFR 1.750 03 Jun, 2024 US8669281
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9512165
Withdrawal of Application for PTE 01 May, 2024 US9090558
Withdrawal of Application for PTE 01 May, 2024 US10080733
Requirement for information sent under 37 CFR 1.750 04 Apr, 2024 US9090558
Requirement for information sent under 37 CFR 1.750 04 Apr, 2024 US10080733
Requirement for information sent under 37 CFR 1.750 04 Apr, 2024 US8669281
Notice of Final Determination -Election Required 29 Mar, 2024 US8669281
Notice of Final Determination -Election Required 29 Mar, 2024 US9090558
Notice of Final Determination -Election Required 29 Mar, 2024 US10080733
Expire Patent 18 Mar, 2024 US10555993
Initial letter Re: PTE Application to regulating agency 05 Mar, 2024 US10172871
Initial letter Re: PTE Application to regulating agency 05 Mar, 2024 US10342810
Initial letter Re: PTE Application to regulating agency 05 Mar, 2024 US11236121
Initial letter Re: PTE Application to regulating agency 05 Mar, 2024 US9512165


Biogen Inc's Drug Patent Litigations

Biogen Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 01, 2015, against patent number US8399514. The petitioner Coalition for Affordable Drugs V LLC, challenged the validity of this patent, with Biogen MA Inc. as the respondent. Click below to track the latest information on how companies are challenging Biogen Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8399514 July, 2018 Final Written Decision
(03 Feb, 2023)
Biogen MA Inc. Mylan Pharmaceuticals Inc. et al.
US8399514 March, 2019 Terminated
(11 Sep, 2019)
Biogen MA Inc. Sawai USA, Inc. et al.
US8399514 September, 2015 FWD Entered
(21 Mar, 2017)
Biogen Idec MA Inc Coalition For Affordable Drugs V LLC
US8759393 April, 2015 Terminated-Denied
(27 Oct, 2015)
Biogen International GmbH Coalition For Affordable Drugs V LLC
US8399514 May, 2015 Terminated-Denied
(02 Sep, 2015)
Biogen MA Inc. Coalition for Affordable Drugs V LLC


Biogen Inc Drug Patents' Oppositions Filed in EPO

Biogen Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 05, 2014, by Zentiva K.S.. This opposition was filed on patent number EP08725256A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP13169139A Apr, 2023 BIOGARAN Granted and Under Opposition
EP13169139A Apr, 2023 Dr. Schön, Neymeyr & Partner Patentanwälte mbB Granted and Under Opposition
EP13169139A Apr, 2023 Kraus & Weisert Patentanwälte PartGmbB Granted and Under Opposition
EP13169139A Apr, 2023 Glenmark Pharmaceuticals Europe Ltd Granted and Under Opposition
EP13169139A Apr, 2023 Accord Healthcare Ltd Granted and Under Opposition
EP13169139A Apr, 2023 Adalvo Ltd. Granted and Under Opposition
EP13169139A Mar, 2023 TEVA PHARMACEUTICAL INDUSTRIES, LTD. Granted and Under Opposition
EP13169139A Feb, 2023 Stada-Arzneimittel Aktiengesellschaft Granted and Under Opposition
EP13169139A Oct, 2022 G. L. Pharma GmbH Granted and Under Opposition
EP13169139A Sep, 2022 Zentiva k.s. Granted and Under Opposition
EP13169139A Jul, 2022 Polpharma S.A. Granted and Under Opposition
EP13169139A Jul, 2022 Hexal AG Granted and Under Opposition
EP13169139A Jul, 2022 neuraxpharm Arzneimittel GmbH Granted and Under Opposition
EP13169139A Jul, 2022 Generics [UK] Limited (trading as Mylan) Granted and Under Opposition
EP14767892A Mar, 2019 Generics (UK) Ltd Granted and Under Opposition
EP14767892A Mar, 2019 Hexal AG Granted and Under Opposition
EP14767892A Mar, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP08725256A Feb, 2014 Actavis Group PTC ehf Revoked
EP08725256A Feb, 2014 Synthon B.V. Revoked
EP08725256A Feb, 2014 Forward Pharma A/S Revoked
EP08725256A Feb, 2014 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Revoked
EP08725256A Feb, 2014 Generics [UK] Limited Revoked
EP08725256A Feb, 2014 Gallafent, Antony Xavier Revoked
EP08725256A Feb, 2014 European Opposition Limited Revoked
EP08725256A Feb, 2014 G. L. Pharma GmbH Revoked
EP08725256A Feb, 2014 Hexal AG Revoked
EP08725256A Feb, 2014 Zentiva k.s. Revoked


Biogen Inc's Family Patents

Biogen Inc drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 31.4% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Biogen Inc Drug List

Given below is the complete list of Biogen Inc's drugs and the patents protecting them.


1. Tecfidera

Tecfidera is protected by 15 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10959972 Methods of treating multiple sclerosis 16 Nov, 2035
(11 years from now)
Active
US11007166 Methods of treating multiple sclerosis 16 Nov, 2035
(11 years from now)
Active
US11007167 Methods of treating multiple sclerosis 16 Nov, 2035
(11 years from now)
Active
US11129806 Methods of treating multiple sclerosis 16 Nov, 2035
(11 years from now)
Active
US11246850 Methods of treating multiple sclerosis 16 Nov, 2035
(11 years from now)
Active
US10391160 Dimethyl fumarate and vaccination regimens 13 Mar, 2035
(10 years from now)
Active
US10555993 Dimethyl fumarate and vaccination regimens 13 Mar, 2035
(10 years from now)
Active
US10994003 Dimethyl fumarate and vaccination regimens 13 Mar, 2035
(10 years from now)
Active
US8399514 Treatment for multiple sclerosis 07 Feb, 2028
(3 years from now)
Active
US7320999 Dimethyl fumarate for the treatment of multiple sclerosis 18 May, 2020
(4 years ago)
Expired
US6509376 Utilization of dialkyfumarates 29 Oct, 2019
(4 years ago)
Expired
US8759393 Utilization of dialkylfumarates 04 Jul, 2018
(6 years ago)
Expired
US7619001 Utilization of dialkylfumarates 01 Apr, 2018
(6 years ago)
Expired
US7803840 Utilization of dialkylfumarates 01 Apr, 2018
(6 years ago)
Expired
US8524773 Utilization of dialkylfumarates 01 Apr, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tecfidera's drug page


2. Vumerity

Vumerity is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10080733 Prodrugs of fumarates and their use in treating various diseases 20 Sep, 2033
(8 years from now)
Active
US8669281 Prodrugs of fumarates and their use in treating various diseases 20 Sep, 2033
(8 years from now)
Active
US9090558 Prodrugs of fumarates and their use in treating various diseases 20 Sep, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vumerity's drug page


3. Zurzuvae

Zurzuvae is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11884696 Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid 24 Dec, 2037
(13 years from now)
Active
US11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid 23 Aug, 2037
(12 years from now)
Active
US10172871 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof 17 Apr, 2034
(9 years from now)
Active
US10342810 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof 17 Apr, 2034
(9 years from now)
Active
US9512165 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof 17 Apr, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurzuvae's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Biogen Inc News

FDA in the United States Approves Two Biosimilars for Popular Eye Medication Eylea

11 Oct, 2024

US Doctors Anticipate Changes in Lupus Treatments

17 Sep, 2024

Late-stage trial shows effectiveness of Incyte's drug for blood cancer

15 Aug, 2024

Biogen exceeds projections and raises future forecasts due to success of Alzheimer's drug Leqembi and other new treatments.

01 Aug, 2024

See More